東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The Fault is in Our TCRS: Searching ...

Gejman, Ron S.

FindBook

Google Book

Amazon

博客來

The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies./
作者:	Gejman, Ron S.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	135 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-03, Section: B.
Contained By:	Dissertations Abstracts International80-03B.
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10928022
ISBN:	9780438488281

The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies.
Gejman, Ron S.

The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 135 p.

Source: Dissertations Abstracts International, Volume: 80-03, Section: B.

Thesis (Ph.D.)--Weill Medical College of Cornell University, 2018.

This item must not be sold to any third party vendors.

T cell receptor (TCR)-based therapeutic cells and agents have emerged as a new class of effective cancer therapeutics against intracellular cancer-associated proteins. These agents rely on presentation of short peptides derived from cellular, viral or phagocytosed proteins on major histocompatibility complex (MHC). However, cross-reactivities of these agents to off-target cells and tissues are poorly understood, difficult to predict, and have resulted in serious, sometimes fatal, adverse events. We have developed a mammalian, minigene-based method (termed "PresentER") that encodes MHC-I peptide ligands for functional immunological assays as well as for determining the reactivities and potential cross-reactivities of TCR-like therapeutic agents against libraries of MHC-I ligands. This system is highly specific to, and entirely dependent on, the genetically encoded MHC peptide sequence, because it does not require proteasome cleavage, transporter associated with antigen processing (TAP) or processing, for immune presentation. Cells expressing PresentER antigens can be bound by TCR and TCR mimic (TCRm) antibodies, activate antigen-specific T cells, lead to antigen-specific cell death in vitro and tumor rejection in vivo. Using PresentER in a pooled library screen, we find dozens of MHC-I ligands encoded in the human proteome that are cross-reactive with two TCR mimic antibodies and are not predictable by other methods. We extend the use of this method to find the targets of an engineered TCR. Finally, we leverage the ability to generate tumors comprised of libraries of MHC-I ligands to study the determinants of MHC-I peptide immunogenicity in vivo. Surprisingly, we show that highly immunogenic tumor antigens (encoded by PresentER) do not lead to early immune-mediated tumor rejection in vivo when the fraction of cells bearing each antigen ("clonal fraction") is low. Moreover, the clonal fraction that must bear an antigen in order to lead to rejection of immunogenic tumor subclones is dependent on the individual antigen itself. These data indicate that tumor neoantigen heterogeneity has an underappreciated impact on the ability of the immune system to detect and eliminate cancer cells and has implications for the prioritization of antigens in the design of novel antigen-specific immunotherapeutics such as cancer vaccines.

ISBN: 9780438488281Subjects--Topical Terms:

517296
Molecular biology.

The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies.
LDR:03502nmm a2200337 4500 001 2207222
005 20190916101804.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438488281
035 $a (MiAaPQ)AAI10928022
035 $a (MiAaPQ)med.cornell:10429
035 $a AAI10928022
040 $a MiAaPQ $c MiAaPQ
100 1 $a Gejman, Ron S. $3 3434177
245 1 4 $a The Fault is in Our TCRS: Searching for on and Off-targets in T Cell Receptor Based Therapies.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 135 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-03, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Scheinberg, David A.
502 $a Thesis (Ph.D.)--Weill Medical College of Cornell University, 2018.
506 $a This item must not be sold to any third party vendors.
520 $a T cell receptor (TCR)-based therapeutic cells and agents have emerged as a new class of effective cancer therapeutics against intracellular cancer-associated proteins. These agents rely on presentation of short peptides derived from cellular, viral or phagocytosed proteins on major histocompatibility complex (MHC). However, cross-reactivities of these agents to off-target cells and tissues are poorly understood, difficult to predict, and have resulted in serious, sometimes fatal, adverse events. We have developed a mammalian, minigene-based method (termed "PresentER") that encodes MHC-I peptide ligands for functional immunological assays as well as for determining the reactivities and potential cross-reactivities of TCR-like therapeutic agents against libraries of MHC-I ligands. This system is highly specific to, and entirely dependent on, the genetically encoded MHC peptide sequence, because it does not require proteasome cleavage, transporter associated with antigen processing (TAP) or processing, for immune presentation. Cells expressing PresentER antigens can be bound by TCR and TCR mimic (TCRm) antibodies, activate antigen-specific T cells, lead to antigen-specific cell death in vitro and tumor rejection in vivo. Using PresentER in a pooled library screen, we find dozens of MHC-I ligands encoded in the human proteome that are cross-reactive with two TCR mimic antibodies and are not predictable by other methods. We extend the use of this method to find the targets of an engineered TCR. Finally, we leverage the ability to generate tumors comprised of libraries of MHC-I ligands to study the determinants of MHC-I peptide immunogenicity in vivo. Surprisingly, we show that highly immunogenic tumor antigens (encoded by PresentER) do not lead to early immune-mediated tumor rejection in vivo when the fraction of cells bearing each antigen ("clonal fraction") is low. Moreover, the clonal fraction that must bear an antigen in order to lead to rejection of immunogenic tumor subclones is dependent on the individual antigen itself. These data indicate that tumor neoantigen heterogeneity has an underappreciated impact on the ability of the immune system to detect and eliminate cancer cells and has implications for the prioritization of antigens in the design of novel antigen-specific immunotherapeutics such as cancer vaccines.
590 $a School code: 0967.
650 4 $a Molecular biology. $3 517296
650 4 $a Pharmacology. $3 634543
650 4 $a Immunology. $3 611031
690 $a 0307
690 $a 0419
690 $a 0982
710 2 $a Weill Medical College of Cornell University. $b Pharmacology. $3 3434178
773 0 $t Dissertations Abstracts International $g 80-03B.
790 $a 0967
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10928022